Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes-Reference-Cited by-同舟云学术

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes

Published:2016-09-01 Issue:9 Volume:128 Page:1226-1233
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Kortüm K. Martin¹²,Mai Elias K.³⁴,Hanafiah Nur H.³,Shi Chang-Xi¹,Zhu Yuan-Xiao¹,Bruins Laura¹,Barrio Santiago¹,Jedlowski Patrick¹,Merz Maximilian⁴,Xu Jing³⁵,Stewart Robert A.¹,Andrulis Mindaugas⁵,Jauch Anna⁶,Hillengass Jens⁴,Goldschmidt Hartmut⁴⁷,Bergsagel P. Leif¹,Braggio Esteban¹,Stewart A. Keith¹⁸,Raab Marc S.³⁴^ORCID

Affiliation:

1. Department of Hematology, Mayo Clinic in Arizona, Scottsdale, AZ;

2. Department of Internal Medicine II, Würzburg University Hospital, Würzburg, Germany;

3. Max-Eder Group “Experimental Therapies for Hematologic Malignancies,” Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany;

4. Department of Internal Medicine V, and

5. Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany;

6. Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany;

7. National Center of Tumor Diseases, Heidelberg, Germany; and

8. Center for Individualized Medicine, Mayo Clinic, Rochester, MN

Abstract

Key Points The incidence of mutations within the MAPK pathway, the CRBN pathway, and TP53 is significantly increased in drug-refractory MM. Mutations in CRBN might contribute to IMiD resistance in drug-refractory MM.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/128/9/1226/1398603/1226.pdf

Reference60 articles.

1. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.;Walker;J Clin Oncol,2015

2. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.;Bolli;Nat Commun,2014

3. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.;Lohr;Cancer Cell,2014

4. Interim Analysis of the MMRF CoMMpass Trial: Identification of Novel Rearrangements Potentially Associated with Disease Initiation and Progression [abstract].;Lonial;Blood,2014

5. Identification of Initiating Trunk Mutations and Distinct Molecular Subtypes: An Interim Analysis of the MMRF CoMMpass Study [abstract].;Keats;Blood,2015

Cited by 176 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cereblon-Targeting Ligase Degraders in Myeloma;Hematology/Oncology Clinics of North America;2024-02

2. Induced protein degradation for therapeutics: past, present, and future;Journal of Clinical Investigation;2024-01-02

3. Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens;Nature Cancer;2023-11-09

4. ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma;Blood Cancer Discovery;2023-11-06

5. High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients;Clinical and Experimental Medicine;2023-10-10